Preclinical studies support the development of novel therapies that target DLL3 in SCLC and possibly other neuroendocrine tumors, and have demonstrated that targeting of DLL3 using an ADC approach inhibits tumor growth (5, 18–20). This evidence concerns the gene DLL3 and neoplasm.